Biotech failure, 2002 Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech failure, 2002

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Elmer who wrote (78)	6/9/2002 4:11:10 AM
From: Alfred W. Post	Read Replies (1) of 130

Biogen vs. Serono Bad for one, good for the other? When Biogen introduced AVENEX as so far the only drug against multiple sclerosis (MS) in 1996, the FDA gave the firm for 7 years a practical monopoly unless a much better product would be invented. With "REBIF " Serono has now such a product and expects to increase its sales from now $380 mio/y til 2005 to become its first billion $ product with a 20% share of the MS market. In the fierce battle between Rebif and Avenex Serono has recently scored a major victory when the FDA forbid Biogen to use unfair and misleading advertising in comparing the two products. This clearly shows that in the eyes of the FDA, Serono's Rebif is a valid if not superior competitor to Biogen's Aventex. The loss of this battle could be one reason for the bad performance of the shares of Biogen. Sales of Aventex accont for appr. 90% of total sales. And what is the loss of Biogen might just as well be the gain for Serono whos stock has fallen along with the market from a high of $30 to now $19 and with considerable recovery potential. Fred

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next